The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think people must remember that the safety and efficacy data must be significant enough for bodies to reimburse the drug, otherwise it will only be used in private practice. Just because its a "bit better" may not be enough for NICE and the SMC to say ok we will pay for that.
However, I don't think this will be an issue, just to keep in mind.
"Avacta are using a proven drug in Doxorubicin so that might increase the chances of success?"
This is the major point, the phase 2 trials are not testing a brand new oncology drug only a delivery and targeting mechanism, hence no need for phase 3 trials, straight to market post phase 2!. So the success percentage must be well over 50%! We are talking about the tolerability of the human body to affirmers and to the accuracy of binding to a cancer growth and delivering the targeted drug with minimal local leakage. This doesn't compare with the proving of a new a drug requiring phase 3 trials, however its not without risk though (nothing ever is!), but should be manageable.
Thank you. I'll need to do more reading to try and get my head round the upside.
Firstly, an existing drug works (to whatever degree).
Secondly, this is why there only needs to be phase one and phase two.
The report you have read is about ALL starter treatments, none of which have the IP being used in AVA6000.
Trust this helps.
Onwards Avacta.
The Ava6000 sounds very exciting but just been reading that an MIT group Wong et al 2019 found only 3.4% of oncology phase one trials succeeded. That sounds to me like an awful lot of what would have been promising products not making it through. Avacta are using a proven drug in Doxorubicin so that might increase the chances of success?
I have left him in the green box where he belongs. Maaaaatt's comment 'you should be a priest' tells me I'm doing the right thing.
I too have unfiltered wyndrum.
I can't log onto LSE at work, so don't have the ability to filter people and now read pretty much everyone's posts.
I'm not sure why I ever filtered him. Possibly got caught up in the moment of collective wyndrum hating.
AND he now knows how to space his work out.
Sort of thing ES32 used to come out with
What a strange comment ndn.
"Maybe she's tied up in the attic".. ( you guys kill me).....so when you Nd, put your money in a pension do I have to assume the fund manager had also kept you incapacitated somewhere….?
Ndn, or one is in your wife”s name
I think you are absolutely correct Mowz in saying that newbies will have to learn the hard way. It was just a response more to Radds asking me to express an opinion as my indifference may have been off putting to said newbies.
W, this weekends fantasy & pension advice post's were ,I'm sure down to 'slow news' and crap rugby (England), can't imagine newbies would pile in first thing this morning on the back of harmless dreams.
We are nearly there with the LFT Wyn. Then you can move on to warning us not to be overconfident with the cancer therapy ; )
Wyn - thanks for the spacing! ;) I think balance is the key. I think this share has been really difficult for some. A lot of people have put a HUGE amount of research into it and the November Vaccine drop and the deafening silence was difficult to stomach as many have put in excessive exposure (including me) to this share (mainly due to the huge amount of research put in).
So whilst I feel your cautions are absolutely justified (and indeed I share them to an extent) I think this motive to protect newbies from jumping in without research is somewhat indisguishable from some trolling that does go on here. This BB has become a bit of a 2nd job for some (main job even?) and has its characters that have made it an interesting place over the last year.
So in short (I'm rambling now) I think your caution is wise, but at the same time it sometimes lacks balance given where we have been in the last year. We are in a much more certain place, and I agree the £20 thoughts are premature but I don't mind a few people day dreaming - I kind of think they deserve it. In terms of risk to newbies, in all likelihood they either won't research it and jump in (regardless of what is posted here) or they will research and jump in at an appropriate level. If the former, they have a lot to learn... I topped up above 200 last May after first buying in at 57.5 and loads of places in between. I got my average down to 140 after the vaccine news and I have learnt a lot in the last 12 months. You probably won't save a newbie from him/herself. I think most have to learn the hard way.
Radds, what newbies should take out from this board is not to become emotional involved with this (or any stock).
I can't comment on the science of AVCT so I take the presentations at face value.
I have some experience in interpreting charts with a reasonable success rate
And I have some experience in understanding the psychological pulls of trading/investing.
You only have to read the weekends posts to understand that many here are already dreaming of what to do with all the money they are going to make. That's more dangerous to newbies imo, then whether or not I express an "opinion"
Can’t believe I’m saying this but I’m actually with Wyn on this one. And thanks for the line spacing, pal!
Steady on everyone, slowly slowly etc.
2 things: (one, I can't be arsed, the second is my opinion should make no difference to anyone.)
Most here have already put me in their box of knowing all about me and nothing I can say or post will ever make them change their minds. (The most absurd and inaccurate is that apparently I am troll and that accusation is routinely repeated !)
I don't know how many times I have told this board that I bought in June and have never sold out at any time. Within a core holding of 40,000 plus shares I have at various times added and sold above that base of 40,000 shares, to de-risk where I thought necessary, and when I thought the risk reward was better again, added back. I have several posts explaining where I added to stock.
If you really care I am up to about 72k of shares now and when I inject a further £40k into my 2 isas I expect, depending on exactly where we are, to add more AVCT.
I 'm sure many here are relieved to know my intentions, and it must be a great relief...….
(PS: I have put in lots of line spaces to make this easier to read for some who struggled with my previous format.)
I have to say - I personally think Wyndrum has been positively bordering on ramping (for him) the last few days... Must be be a good sign?
Whyndy, to assist the newby's can you please use the drop down menu to clearly indicate your position, leaving it as 'no opinion' is not helpful.
Just saying
Wow, tough crowd....
(you don't think having discussion whether we should collectively sell out at £20 per share or not was the tiniest bit rampy…..?)
lol
For me, he's also a pleasant shade of green.
"This stock is practically unrampable!!!!!!!!!"
Oh, I don't know, I'm pretty sure if we put our backs into it we could ……
(you know,given that we don't have a CV test out yet and have continually missed almost every expected deadline, …. just saying... ;o)
Ceo's elsewhere have been getting pelters for lack of same.
Stodgy has reminded us of our CEO's vision.
The funds for our Covid test will enable us to compete with Roche Thermofisher and Abbott.
This stock is practically unrampable!!!!!!!!!